GC Therapeutics Advances TFome™ Platform with Novel Cell Therapies for Multiple Sclerosis and Type 1 Diabetes
核心洞察
GC Therapeutics (搜索) unveiled its initial pipeline programs targeting demyelinating neurological disorders including multiple sclerosis and a regenerative cell therapy for Type 1 diabetes using its TFome™ platform.
The company completed its first Cell State Cookbook™ mapping over 300 human cell states and testing two million transcription factor combinations to enable precision cell state engineering.
Both the FDA and EMA endorsed GCTx's TFome™-enabled development model and supported a streamlined regulatory pathway for the company's pipeline programs.
GC Therapeutics (搜索) (GCTx) announced significant advances in its TFome™ cellular programming platform, unveiling initial pipeline programs for demyelinating neurological disorders including multiple sclerosis and a regenerative cell therapy approach for Type 1 diabetes. The Cambridge-based biotechnology company also appointed Kate Haviland, former CEO of Blueprint Medicines, as chair of its Board of Directors.
Breakthrough Cell Programming Technology
The company completed its first Cell State Cookbook™ (CSC™), mapping epigenomic transitions across more than 300 human cell states and testing over two million transcription factor combinations in living human cells. This comprehensive mapping enables the TFome™ platform to identify fully optimized transcription factor combinations to differentiate induced pluripotent stem cells (iPSCs) into virtually any functional cell type through a single-step, four-day process with greater than 90% efficiency.
"For decades, cell therapy has relied on trial-and-error approaches to cell identity," said Parastoo Khoshakhlagh, Ph.D., co-founder and chief executive officer of GCTx. "At GCTx, we are replacing that paradigm with a system that learns from biology at scale and translates those into new classes of medicines."
The TFome™ platform integrates genome-scale experimental testing with AI foundation models validated in closed-loop biology. Through transcription factor-based cell fate programming, the system is designed to yield first-in-class and best-in-class off-the-shelf cell therapy products up to 100 times more rapidly than conventional methods of cell differentiation with improved potency, efficiency, quality and cost.
Pipeline Programs and Regulatory Progress
GCTx's initial focus centers on developing cell therapies for neurological and metabolic diseases. The company remains on track to name a development candidate for its novel first-in-class neurology program targeting demyelinating diseases in 2026, while progressing discovery work on its best-in-class cell therapeutic approach for treating Type 1 diabetes.
Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have provided productive feedback on GCTx's development approach. The regulators endorsed the TFome™-enabled development model and supported a streamlined regulatory pathway across the pipeline, marking a significant milestone for the platform's clinical advancement.
Leadership Appointment
Kate Haviland brings decades of biotechnology leadership experience to her new role as board chair. She most recently served as president and chief executive officer of Blueprint Medicines until its acquisition by Sanofi in 2025, having previously held roles as chief operating officer and chief business officer. Her experience spans multiple organizations including Idera Pharmaceuticals, Sarepta Therapeutics, PTC Therapeutics and Genzyme.
"GC Therapeutics (搜索) is tackling the most persistent challenges in cell therapy with a platform that is both scientifically compelling and operationally scalable," said Haviland. "The company's approach to cellular programming, manufacturing, and regulatory strategy positions it as a leader who can meaningfully expand patient access to transformative therapies."
Platform Capabilities and Future Applications
The TFome™ platform represents the world's first complete collection of human transcription factors, enabling what the company describes as a "plug-and-play" cellular programming system. The platform's modularity and scalability are designed to streamline development, manufacturing, and regulatory engagement across multiple therapeutic applications.
GCTx has positioned itself to be the first company in the iPSC-based cell therapy space to pursue multiple cell products from one starting point using a similar manufacturing strategy. The Cell State Cookbook™ powers predictive AI foundation models that capture key features of cell state control and enable rapid identification of optimized transcription factor programs, significantly streamlining discovery for both cell therapy development and in vivo reprogramming.
The TFome™ technology was invented and developed by a team of scientists in the laboratory of Professor George Church, Ph.D., at Harvard Medical School and the Wyss Institute. Founded in 2019, GCTx has raised $75 million to date from leading life sciences investors and is positioned to expand its platform capabilities into in vivo reprogramming and cellular rejuvenation applications.